Month of BID pimecrolimus best in facial seborrheic dermatitis

Month of BID pimecrolimus best in facial seborrheic dermatitis

(HealthDay)—Pimecrolimus 1 percent cream applied twice a day for four weeks seems to be the best regimen for patients with facial seborrheic dermatitis, according to a study published online June 7 in the Journal of Cosmetic Dermatology.

Juemin Zhao, M.D., from Fudan University in Shanghai, and colleagues examined the comparative efficacy of pimecrolimus 1 percent cream with different treatment regimens in 30 patients with facial seborrheic dermatitis. The regimens included treatment with topical pimecrolimus cream twice daily for two weeks then a moisturizer cream twice daily for two weeks (Group 1), pimecrolimus cream 1 percent twice daily for two weeks then once daily for two weeks (Group 2), and a consecutive course of pimecrolimus cream twice daily for four weeks (Group 3).

The researchers observed significant decreases in the clinical severity scores of all three regimens at week four (P < 0.01). Compared with groups 1 and 2, group 3 had a more remarkable improvement in total severity score (P < 0.05); in group 3 this effect was maintained to the end of the study. All three groups had significantly improved life quality at week four (P < 0.001), while no significant difference was seen between the groups in improvement of .

"We recommend pimecrolimus 1 percent could be applied twice a day
for 4 weeks to treat seborrheic dermatitis," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Citation: Month of BID pimecrolimus best in facial seborrheic dermatitis (2017, June 20) retrieved 28 March 2024 from https://medicalxpress.com/news/2017-06-month-pimecrolimus-facial-seborrheic-dermatitis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Low-dose isotretinoin therapeutic for seborrhea

0 shares

Feedback to editors